Home Blog Page 884

TraceLink VP of OPUS Core Platform Development Jerry Meyer Named a 2026 Supply & Demand Chain Executive “Pros to Know” Honoree

By
Advertorial Desk
-

This award recognizes leadership in advancing AI-driven orchestration across life sciences supply chains

Summary
TraceLink Vice President of OPUS Core Platform Development Jerry Meyer has been named a 2026 Pros to Know winner by Supply & Demand Chain Executive. The recognition highlights his leadership in advancing governed, production-ready agentic AI and digital orchestration across regulated life sciences supply chains.

BOSTON, March 26, 2026 /PRNewswire/ — TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced that Supply & Demand Chain Executive named Jerry Meyer, Vice President of OPUS Core Platform Development at TraceLink, a winner of this year’s Pros to Know award in the Leaders in Excellence category. The award recognizes outstanding executives whose accomplishments offer a roadmap for leveraging the supply chain for competitive advantage.

Jerry oversees the architecture of the Orchestration Platform for Universal Solutions (OPUS), TraceLink’s industrial-grade multienterprise platform enabling secure, governed collaboration across global life sciences and healthcare networks. Over the past year, Jerry has led major advancements in TraceLink’s digital network and AI architecture, accelerating the deployment of regulated supply chain capabilities while embedding governed agentic AI directly into operational workflows across the end-to-end life sciences and healthcare supply chain.

“The future of regulated supply chains is agentic, intelligent, and network-driven,” said Shabbir Dahod, President and CEO of TraceLink. “It begins with a unified digital network foundation that requires each company to integrate only a single time to the network, and begin accessing real-time data available across the end-to-end supply chain. On top of that foundation, organizations can leverage no-code solution creation capabilities to rapidly deploy enterprise AI agents responsibly and at tremendous scale. Jerry and his team are bringing that vision to life and advancing AI-powered orchestration across global life sciences supply chains.”

From Platform Evolution to Industry Transformation
Meyer’s leadership has driven a deliberate transformation of the OPUS platform—first strengthening its digital foundation, then purpose‑building it for AI readiness. The result is a resilient, metadata‑driven infrastructure capable of safely operationalizing AI in one of the world’s most highly regulated supply chain environments.

  • Building an AI‑ready digital backbone for industry-wide agility: By expanding TraceLink’s metadata-driven, no-code architecture, Meyer and team evolved OPUS from a compliance-focused platform into a scalable digital backbone for multienterprise supply chain execution. Deployment timelines for new capabilities were reduced from months to weeks, while multienterprise processes, partner interactions, and regulatory requirements were structured into governed, interoperable workflows. What began as a compliance foundation now serves as an AI-ready operating layer—enabling life sciences and healthcare companies to adapt in real time to changing global requirements, reduce disruption risk, and translate regulatory readiness into broader operational agility, resilience, and competitive advantage.
  • Activating governed AI on a purpose-built foundation: With OPUS architected for no-code, enterprise AI agent readiness, Meyer and team led the transformation that embedded governed agentic AI directly into customer and trade partner solutions natively. Because AI operates on structured process definitions, role-based controls, and auditable transaction and process data, Assistants and Agents can function within defined responsibilities, domain intelligence, human oversight, and full auditability. Rather than layering AI onto fragmented systems, this approach ensures automation enhances regulatory integrity—enabling faster exception resolution, improved supply assurance, and more coordinated multienterprise execution while preserving transparency and trust.

Under his leadership, TraceLink launched its first production AI Assistants and Agents—bringing governed AI into exception management, procure-to-pay, order-to-cash, supply assurance, and multienterprise coordination. Meyer has helped to position OPUS not just as a digital network, but as an intelligent, resilient operating layer for the global life sciences ecosystem.

“Building an effective agentic workforce requires more than just AI models—it requires the right architecture,” said Jerry Meyer. “The quality and flexibility of your no-code AI agent framework ultimately defines the quality of your digital workforce. With OPUS, we’ve built an industrial platform that combines an integrated information backbone across internal and external supply chain systems, governed AI with full GxP auditability, and a no-code framework for defining agents through structured roles and operating procedures. The result is a new operating model where intelligent agents work alongside people to orchestrate supply chain processes with the right information, context, and accountability at every step.”

“When it comes to overcoming supply chain disruption, this year’s pack of supply chain leaders left no stone unturned,” says Marina Mayer, editor-in-chief of Food Logistics and Supply & Demand Chain Executive and co-founder of the Women in Supply Chain Forum. “From AI implementation and warehouse automation to last-mile accuracy and returns management, they innovated, developed, and executed on all cylinders, providing solutions, technologies, and processes that move product from Point A to Point B in a way that almost seems seamless. And every year, I am honored to celebrate these supply chain professionals.”

To learn more about how TraceLink is advancing agentic orchestration to enable AI-driven supply chain execution in life sciences and healthcare, visit tracelink.com.

View the full list of winners: https://sdce.me/h6ychkwi. Learn more about the awards: https://www.SDCExec.com/awards

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by linking more than 291,000 healthcare and life sciences entities through its Business-to-Network Integrate-Once™ network. Leading companies trust TraceLink to deliver complete global digitalization, visibility, and traceability of healthcare products, ensuring that every patient receives the medicines they rely on, safely, securely, and on time.

About Supply & Demand Chain Executive
Supply & Demand Chain Executive is the only supply chain publication covering the entire global supply chain, focusing on trucking, warehousing, packaging, procurement, risk management, professional development and more. Supply & Demand Chain Executive and its sister publication, Food Logistics, also operate SCN Summit and the Women in Supply Chain Forum. Go to www.SDCExec.com to learn more.

About IRONMARKETS
IRONMARKETS, formerly known as AC Business Media, is a leading business-to-business media and buyer engagement platform with a portfolio of renowned brands in heavy construction, asphalt, concrete, paving, rental, sustainability, landscape, manufacturing, logistics, and supply chain markets. IRONMARKETS delivers relevant, cutting-edge content through its industry-leading digital properties, trade shows, conferences, videos, magazines, webinars, and newsletters. Learn more at https://www.iron.markets.

Globally Ranked in the Top 3% Design Schools, Domus Academy opens new scholarship opportunities

By
Advertorial Desk
-

MILAN, March 26, 2026 /PRNewswire/ — Domus Academy has achieved a landmark result in the QS World University Rankings by Subject 2026, one of the most authoritative university rankings in the world. In the Design discipline, the Academy has placed 62nd out of 2,239 institutions, positioning itself in the global Top 3% and firmly establishing its place among the world’s elite design schools.

domus academy
domus academy

This result marks a path of steady and measurable growth. The school has reached strong results across key indicators, including Academic Reputation — reflecting how the global academic community evaluates teaching quality — and Employer Reputation, which shows how highly international companies value its graduates. Both figures reflect the school’s standing within the global creative and design industry.

The rankings translate directly into real-world outcomes. 91% of Domus Academy graduates find employment within one year of completing their studies, with a 94% job satisfaction rate — figures that place Domus Academy among the most career-effective design institutions worldwide. The return on educational investment is equally compelling: graduates typically reach payback on their tuition within just 16 to 21 months, making it one of the strongest value propositions in international design education.

To support the next generation of international talent, Domus Academy has launched its Competition for Scholarships for the Academic Masters and 2-year Master of Arts programmes starting in Autumn 2026, offering awards of up to €8,000. The application deadline is April 10, 2026.

Domus Academy is a place where future designers experience an open, industry integrated, project based and cross-disciplinary environment. The programmes in the areas of fashion, design and business enable students to work following a learning by designing approach, participating in interdisciplinary workshops with experienced professionals and leading companies.

Its academic offering includes Bachelor of Arts, Master of Arts, and Academic Master’s Programmes — all recognized by the Italian Ministry of Universities and Research (MUR) — spanning Fashion, Design, and Business. It is further enriched by Dual Awards Master’s Programmes, allowing students to obtain an additional qualification recognised by the British academic system.

Over the years, Domus Academy has received numerous awards and recognitions including the Compasso d’Oro Award for the quality of research and academic approach and the Special Badge of Excellence in Learning Experience from The Business of Fashion. In 2025, Domus Academy was ranked by CEOWORLD Magazine among the 30 best fashion schools worldwide. It is also included in the UI GreenMetric World University Rankings and THE Impact Rankings.

To apply for scholarships:
https://competition.domusacademy.com/

For further information, please contact: info@domusacademy.it 

Cyble Secures Dual Industry Honors with Major Wins at Global InfoSec Awards 2026 and Cybersecurity Excellence Awards

By
Advertorial Desk
-

CUPERTINO, Calif., March 26, 2026 /PRNewswire/ — Cyble, a global leader in AI-powered cybersecurity solutions, announced major recognition across two of the industry’s most prestigious award programs. The company received the Gold Award for Threat Intelligence at the Cybersecurity Excellence Awards and earned four honors at the Global InfoSec Awards 2026, presented by Cyber Defense Magazine during RSA Conference 2026.

At the Global InfoSec Awards 2026, Cyble was recognized for:

  • Most Advanced Attack Surface Management
  • Most Advanced Threat Intelligence
  • Publisher’s Choice — Brand Protection
  • Publisher’s Choice — Endpoint Security

These awards highlight the strength of Cyble’s unified cybersecurity platform, spanning attack surface visibility, digital risk protection, and endpoint security for modern enterprises.

The Cybersecurity Excellence Awards Gold recognition underscores Cyble’s innovation in AI-driven threat intelligence. At the core of its platform is Cyble Blaze AI, an autonomous, AI-native engine designed to bridge the gap between rising threat volumes and limited analyst capacity. Operating continuously, Blaze AI enhances speed, precision, and resilience across security operations, enabling organizations to act on real-time intelligence and strengthen proactive defense.

“These recognitions reflect the trust our customers place in us and the outcomes we consistently deliver,” said Beenu Arora, CEO and Co-Founder of Cyble. “Being acknowledged across multiple cybersecurity domains validates our vision of building a unified, proactive security platform that helps organizations stay ahead of increasingly advanced threats. We remain committed to continuous innovation and delivering measurable security impact for our global customers.”

Cyble’s recognition comes as cyber threats grow more complex, targeted, and persistent. Organizations across enterprises, government, and critical infrastructure are shifting from reactive defenses to intelligence-driven security strategies. Cyble continues to lead this transformation with advanced AI capabilities, deeper threat visibility, and scalable solutions tailored to evolving global needs.

With a strong focus on innovation, automation, and actionable intelligence, Cyble remains committed to empowering organizations to strengthen their cybersecurity posture and navigate today’s dynamic threat landscape.

About Cyble

Cyble is an AI-native cybersecurity company providing unified risk intelligence and decision support to enterprises worldwide. Powered by BlazeAI, Cyble’s platform integrates data, advanced reasoning, and automation to enable organizations to respond faster and more confidently. Recognized as a top-rated solution on Gartner Peer Insights, Cyble is praised for its actionable insights and robust platform capabilities.

For more information, visit www.cyble.com

Media Contact: enquiries@cyble.com | +1 678 379 3241

 

 

Keymed Biosciences Announces 2025 Annual Results and Business Updates

By
Advertorial Desk
-

BEIJING, March 26, 2026 /PRNewswire/ — Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company’s 10th anniversary and a pivotal year in its transition from R&D to commercialization.

Revenue Leaps Forward, Supporting Long-Term Stable Growth

Since its founding in 2016, Keymed has built a pipeline of over 50 programs, with more than 10 in clinical development, three indications successfully launched, six core technology platforms continuously upgraded, over 10 external partnerships established, and planned production capacity exceeding 100,000 liters.

In terms of financial performance, the company achieved a significant revenue increase. Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year increase. This included around RMB 310 million from sales of the core product Kangyueda® and approximately RMB 410 million from collaboration income. The company maintained steady R&D investment, with R&D expenses of approximately RMB 720 million. As of December 31, 2025, cash reserves stood at approximately RMB 1.96 billion, providing ample funding to support core pipeline development and long-term business growth.

Core Product Commercialization in Full Swing, Continuous Expansion of Indication Footprint

As of the date of this announcement, the new drug applications of Kangyueda® for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyps (CRSwNP) and seasonal allergic rhinitis (SAR) have been approved by the National Medical Products Administration (NMPA). Since January 2026, all launched indications of Kangyueda® and both of its packaging forms (vials and pre-filled auto-injector pens) have been included in the National Reimbursement Drug List of China, significantly enhancing affordability and accessibility for Chinese patients.

During the Reporting Period, revenue for sales of Kangyueda® amounted to approximately RMB310 million. In January 2026, the new drug applications for Stapokibart for the treatment of adolescents with moderate-to-severe AD were accepted by the NMPA. Simultaneously, we are advancing a Phase III clinical study to evaluate the efficacy and safety of Stapokibart in child subjects with moderate-to-severe AD, and as of the date of this announcement, patient enrollment is in progress. Additionally, in 2025, we continuously proceeded with a Phase III clinical study of Stapokibart injection in patients with prurigo nodularis (PN). This clinical study has completed the patient enrollment in April 2025.

Global Partnerships Accelerate, Milestone Payments Validate Pipeline Value

In 2025, the company advanced several core pipeline programs through out-licensing deals, accelerating clinical development and unlocking overseas value for early-stage assets at an accelerated pace. Multiple business development achievements continued to validate the company’s platform innovation potential and diverse partnership model, providing sustained momentum for subsequent in-house R&D and pipeline advancement.

  • CMG901 (AZD0901, Claudin 18.2 ADC), a first-in-class Claudin 18.2 ADC globally, has received Fast Track and Orphan Drug Designations from the FDA, as well as Breakthrough Therapy Designation from the CDE. Following its out-licensing to AstraZeneca for global development, multiple global Phase III clinical trials are being rapidly advanced. In February 2026, the first subject was dosed in this clinical trial, triggering a milestone payment subject to the terms and conditions of the license agreement. In early March 2026, KYM Biosciences Inc. (a 70% non-wholly-owned subsidiary of the Group) received the relevant milestone payment totaling US$45 million.
  • CM336 (BCMA x CD3 bispecific antibody) was out-licensed to Ouro Medicines for global development (excluding Greater China). Open-label, multi-country basket studies are underway in the United States and Australia for relapsed/refractory autoimmune hemolytic anemia (AIHA), primary immune thrombocytopenia (ITP), and other autoimmune cytopenias, with the first cohort of patients having completed dosing. Basket studies have also been initiated for active, autoantibody-positive Sjögren’s syndrome and idiopathic inflammatory myopathy. In January 2026, CM336 was granted Fast Track Designation (FTD) by the FDA for the treatment of AIHA and ITP.

In March 2026, Ouro Medicines announced that Gilead Sciences would acquire Ouro Medicines through a merger. The Merger Agreement provides for an upfront payment at Closing of US$1,675 million, subject to customary adjustments, and contingent milestone payment of up to US$500 million, for a maximum total of US$2,175 million. It is expected that based on the Company’s equity interest in Ouro Medicines, the Group will receive an initial payment of approximately US$ 250 million, and contingent milestone payment of up to approximately US$ 70 million, for a maximum total of approximately US$320 million. The final consideration receivable by the Group is subject to the achievement of relevant milestones as well as the shareholders agreement amongst the Ouro Medicines shareholders.

  • CM355 (CD20 x CD3 bispecific antibody) : In January 2025, the company entered into a license agreement with Prolium, granting exclusive rights for global development in non-oncology indications and for oncology indications outside Asia. Keymed and its partner InnoCare received a combined upfront and near-term payment of $17.5 million, and are eligible for milestone payments and tiered royalties totaling up to $502.5 million, as well as a minority equity interest in Prolium. As of the date of this announcement, Prolium announced the initiation of dosing in healthy subjects in a single dose-escalation study of CM355/PRO-203, and expects to initiate an international multi-center Phase I/II clinical study for the treatment of systemic sclerosis (SSc) in the second quarter of 2026, and will also initiate therapeutic studies for other B-cell-driven severe autoimmune diseases within 2026. Additionally, in an investigator-initiated exploratory study, 5 patients with refractory advanced systemic lupus erythematosus (SLE) (all accompanied by lupus nephritis) are undergoing treatment evaluation.
  • CM313 (CD38 antibody) : In January 2025, the company entered into an exclusive license agreement with Timberlyne Therapeutics for global development (excluding Greater China), receiving $30 million in upfront and near-term payments, and became the largest shareholder of Timberlyne.

Promising Pipeline Data Highlights Best-in-Class Potential

  • CM512 (TSLP x IL-13 bispecific antibody) : The Phase I study has met all study endpoints. Data showed a half-life of up to 70 days, supporting the potential for extended dosing intervals. Notably, 50% of patients in the 300 mg group achieved EASI-75 at Week 6 post-first dose, compared to 7% in the placebo group. At Week 12, EASI-75 and EASI-90 response rates in the 300 mg dose group reached 58.3% and 41.7%, respectively, versus 21.4% and 0% in the placebo group. At Week 24, response rates remained stable across all endpoints and were significantly superior to placebo. Multiple Phase II studies for CM512 have been initiated across indications including chronic rhinosinusitis with nasal polyps (CRSwNP), moderate-to-severe atopic dermatitis (AD) in adults, moderate-to-severe asthma, moderate-to-severe chronic obstructive pulmonary disease (COPD), and chronic spontaneous urticaria (CSU). Notably, the Phase II study in CRSwNP has completed enrollment of 120 target patients.
  • CM336 (BCMA x CD3 bispecific antibody) : Data from the Phase II dose-expansion cohort in relapsed/refractory multiple myeloma (RRMM) showed an objective response rate (ORR) of 95.2% in the target dose group, with a ≥ complete response (≥CR) rate of 76.2%, a minimal residual disease (MRD) negativity rate of 100%, and a 12-month progression-free survival (PFS) rate of 95.2%. The Phase III study was initiated in the second half of 2025.

In 2025, we continuously proceeded with a Phase I/II clinical study to assess CM336 injection for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). As of July 2025, in the Phase II dose-expansion stage, only 4.7% of subjects experienced Grade 2 cytokine release syndrome (CRS) events, with no immune effector cell-associated neurotoxicity syndrome (ICANS) events occurring. The objective response rate (ORR) in the target dose group was 95.2%, the rate of complete response (CR) or better was 76.2%, the minimal residual disease (MRD) negativity rate was 100%, and the 12-month progression-free survival rate was 95.2%. Concurrently, in the second half of 2025, we initiated a Phase III clinical study to evaluate CM336 monotherapy versus investigator’s choice (standard of care, SOC) in RRMM patients who previously have received at least second-line treatment.

Other Pipeline Programs Progressing Steadily:

  • CM518D1 (CDH17 ADC) : Initiated a Phase I/II clinical trial for advanced solid tumors.
  • CM383 (Aβ protofibril antibody) : Completed patient enrollment in a Phase Ib study for Alzheimer’s disease.
  • CM559 (N3pG Aβ antibody): A Phase I clinical study in healthy male subjects for the treatment of early Alzheimer’s disease was initiated in 2025, with the first subject enrolled in September.
  • CM326 (TSLP antibody) : Led by CSPC Pharmaceutical Group, clinical studies for multiple indications are underway. A Phase III clinical study for moderate-to-severe asthma completed enrollment of the first subject in March 2026, and a Phase III clinical study for CRSwNP was initiated in February 2026.
  • CM350 (GPC3 x CD3 bispecific antibody) : Phase I/II study in advanced solid tumors is in dose-escalation phase.
  • CM369/ICP-B05 (CCR8 antibody) : Phase I dose-escalation trials continue in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Innovative Technology Platforms Continue to Evolve, Forward-Looking Positioning in Chronic Disease

The company has established a diverse set of technology platforms, including Antibodies Discovery Platform, KeyMedSTAR™ (Keymed Superior Topo1i ADC Reagents) ADC Platform, TCE Bispecific Antibodies Platform, VESIR™ (VEhicle for siRNA Delivery) Oligonucleotide Platform, Small Molecule Platform and KeyCND™ (Keymed Central Nervous System Delivery) – Blood-Brain Barrier-Penetrating Antibody Delivery Platform. Leveraging iterative and synergistic platform innovation capabilities, the company continues to efficiently generate high-quality, high-potential innovative medicines, pioneering a blue ocean in the broader chronic disease treatment landscape.

Talent and Organization Continuously Optimized, High-Standard Capacity Development Accelerates

As of December 31, 2025, the company had 1,625 full-time employees, including a commercialization team of over 400 and a drug discovery and clinical operations team of over 430, providing strong talent support for product commercialization and R&D. The Chengdu manufacturing facility currently has three pilot production lines and three commercial production lines, achieving a total capacity of 21,800 liters. A newly added 24,000-liter stainless steel production line has completed installation and commissioning and is about to come into operation. All facilities are designed in compliance with NMPA and FDA cGMP standards, with total planned capacity exceeding 100,000 liters in the future.

The 2025 annual results comprehensively demonstrate the company’s transformative progress in proprietary R&D, clinical advancement, and commercial operations, as well as its broad prospects across diversified technology platforms, innovative partnership-driven global expansion, and value realization on the world stage, underscoring the sustained and steady momentum fueled by original innovation. Keymed will continue to uphold its “patient-centric” philosophy, address unmet clinical needs, and remain committed to proprietary R&D and differentiated innovation, delivering high-quality, affordable innovative therapies to patients, while creating sustainable, long-term value for shareholders, partners, and society.

TINECO RECOGNIZED BY EUROMONITOR INTERNATIONAL AS WORLD’S NO.1 HOUSEHOLD WET & DRY VACUUM CLEANER BRAND FOR FOURTH CONSECUTIVE YEAR

By
Advertorial Desk
-

Tineco continues to lead the global floor care industry through innovation and sustained category growth

SEATTLE, March 26, 2026 /PRNewswire/ — Tineco, a global leader in intelligent floorcare, today announced that Euromonitor International has recognized the company as the world’s No.1 household wet & dry vacuum cleaner brand for the fourth consecutive year*. This recognition from a leading independent provider of strategic market research reinforces Tineco’s continued leadership and momentum within the global smart home cleaning category.

Tineco continues to lead the global floor care industry through innovation and sustained category growth
Tineco continues to lead the global floor care industry through innovation and sustained category growth

Over the past several years, Tineco has played a defining role in transforming household wet & dry vacuum cleaners into an essential category for modern homes. By combining advanced technology with user-centric design, the brand has built a global community of over 24 million users worldwide** while continuing to expand its footprint across key international markets.

According to Euromonitor International, Tineco achieved a 35% global market share in 2025, maintaining its position as the world’s No.1 household wet & dry vacuum cleaner brand for four consecutive years. This milestone highlights the brand’s sustained growth, category leadership, and commitment to delivering high-performance, intelligently designed cleaning solutions trusted by millions of households worldwide.

Tineco’s innovation is reflected across its flagship product lineup, representing its core cleaning categories. The FLOOR ONE S9 Artist Series (S9 Artist Steam PRO, S9 Artist Pro) exemplifies the brand’s leadership in smart wet & dry floor washing, delivering advanced sensing technology and premium design for hard floor care. The PURE ONE A90S showcases powerful cordless vacuum performance with intelligent suction optimization for whole-home cleaning. Meanwhile, the Carpet One Cruiser highlights Tineco’s continued expansion into deep carpet cleaning, offering targeted solutions for more demanding cleaning environments. Together, these flagship products demonstrate Tineco’s commitment to providing comprehensive, high-performance solutions for every surface in the modern home.

“Being recognized as the world’s No.1 household wet & dry vacuum cleaner brand by Euromonitor International for the fourth consecutive year is a significant milestone for Tineco,” said Ling Leng, CEO of Tineco. “This achievement reflects our ongoing commitment to innovation and our mission to simplify everyday life through intelligent technology. As consumer expectations continue to evolve, we remain focused on developing solutions that deliver powerful performance, convenience, and a better overall cleaning experience.”

Since its founding in 1998, Tineco has evolved from a vacuum cleaner manufacturer into a global innovator across smart floorcare, kitchen, and personal care categories. The company introduced the world’s first smart vacuum in 2018 and the first smart wet & dry vacuum cleaner in 2019, helping to establish a new standard for connected home cleaning.

Tineco continues to push the category forward through ongoing product innovation, integrating intelligent features such as real-time sensing, automated performance adjustments, and streamlined maintenance systems. The brand’s expanding portfolio is designed to meet the needs of today’s consumers, offering efficient, high-quality solutions for a wide range of home environments.

Tineco products are available in over 10,000 retail locations worldwide, including major retailers such as Target, Walmart, Best Buy, and Costco, as well as through Amazon and Tineco’s official online store. The company continues to invest in global expansion and product development, with new innovations and category advancements planned for 2026.

To learn more about Tineco and its portfolio of intelligent appliances, please visit us.tineco.com.

*Source: Euromonitor International (Shanghai) Co., Ltd.; measured in terms of the brand’s global retail sales volume (in units) of household wet & dry vacuum cleaners in 2022, 2023, 2024, and 2025. Household wet & dry vacuum cleaners are defined as household cleaners that dispense clean water (or cleaning solution) to wash hard floors and vacuum the dirty water and debris thereafter. Based on research completed in March 2026.

 **Data from Tineco’s official net sales records (Jan. 2020 –March 2026). Tineco has final interpretation rights.

About Tineco
Tineco (“tin-co”) was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 24 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its vision of making life easier through smart technology and continuous innovation. For more information, visit us.tineco.com.

Guidepoint Library Surpasses 100,000 Transcripts, Scaling Real-Time Access to Expert Knowledge

By
Advertorial Desk
-

High-quality expert interviews, now at scale—accessible via MCP and embedded in client workflows.

NEW YORK, March 26, 2026 /PRNewswire/ — Guidepoint today announced that its transcript library has surpassed 100,000 expert interviews, expanding the depth and reach of its proprietary insights. The full dataset is immediate accessible through AskGP in the Guidepoint360 platform or via MCP integration into enterprise AI platforms, enabling teams to leverage expert knowledge alongside internal data in real time.

The milestone reflects a deliberate approach, pairing institutional-grade quality with the volume needed for decision-critical work. Guidepoint adds 5,000+ transcripts monthly creating a continuously evolving knowledge base that supports both deep single-company analysis and timely thematic research across public and private companies globally.

Built for depth, quality, and speed

Guidepoint’s dedicated content team of 300+ delivers decision-ready insight across investing, consulting, and corporate strategy workflows:

  • Single-company depth — Multiple expert perspectives per company, building layered context over time
  • Global perspective — Expansion across US, EMEA, and APAC, spanning developed and emerging markets
  • Public and private markets — Integrated insight across equities and credit, including hard-to-access private companies
  • Live events — 1,400+ hosted teleconferences monthly, along with roundtables, and conferences, offering rapid capture of expert views on breaking news, market disruptions and inflection points
  • Best-in-class compliance — Trusted interviews with vetted experts, 100% compliance reviewed, with quotes directly cited to the source.

The Guidepoint Library integrates directly into how teams already operate, letting clients search and synthesize expert insights in real time, with every answer linked to the original transcripts. The result is fast, defensible analysis, turning conversations into decision-ready intelligence in hours, not days.

Availability

The Guidepoint Library is available now through Guidepoint360, direct-to-client API access, and MCP integration into enterprise AI platforms.

To learn more or request access, contact us at sales@guidepoint.com or reach out to your Guidepoint representative.

About Guidepoint
Guidepoint provides real-time access to expert knowledge, combining human expertise with AI-powered research tools to deliver insight at scale. Backed by a global network of more than 1.75 million subject-matter experts, Guidepoint equips institutional investors, consulting firms, and corporations with the context they need across any company, market, or trend. Through live, asynchronous, and agentic workflows, Guidepoint embeds expert knowledge directly into decision-making, turning answers into action when timing matters most.

CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

By
Advertorial Desk
-

Rapid Advancement Across Core R&D Pipeline

  • The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent safety profile with a ≥Grade 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity. Notably, monotherapy data in lung cancer are encouraging: in first-line NSCLC patients with PD-L1 TPS ≥50%, the ORR reached 90% with a DCR of 100%, while the ORR was 25% in IO-pretreated NSCLC (AGA-negative). Furthermore, significant benefits were observed in patients with heavily pre-treated “cold tumors,” achieving an ORR of 40% in non-clear cell renal cell carcinoma (nccRCC) and 33.3% in soft tissue sarcoma (STS).
  • The global Phase Ib multicenter trial of CS5001 (ROR1 ADC) is being advanced rapidly and efficiently in Australia and China, with its R&D progress ranking among the top two globally. In combination with R-CHOP as a first-line treatment for DLBCL (at doses of 50–90 μg/kg), the CR rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination cohort for later-line DLBCL has also shown favorable safety and a high ORR.

Continued Expansion of Global Commercialization Footprint

  • Since 2025, sugemalimab has secured two new strategic partnerships and received approvals for two additional indications. Its global commercialization footprint now spans over 60 countries and regions, with further collaborations and regulatory filings actively underway.

Breakthroughs in Local Manufacturing and Reimbursement Access

  • GAVRETO® (pralsetinib) successfully obtained approval for local manufacturing in China and was included in the National Reimbursement Drug List (NRDL) for the first time, positioning it for significant sales growth.
  • The domestic supply of AYVAKIT® (avapritinib) has officially commenced, complementing its successful NRDL renewal at the end of last year.

Emerging Preclinical Innovation Pipeline

  • Three internally developed next-generation ADC candidates—CS5007 (EGFR/HER3 ADC), CS5008 (SSTR2/DLL3 ADC), and CS5006 (ITGB4 ADC)—will present preclinical research findings at AACR 2026, with IND submissions planned for 2026.

Solid Financial Position

  • Revenue was RMB269.6 million for the year ended December 31, 2025. The revenue from sales of pralsetinib decreased substantially, which is primarily due to price adjustments of pralsetinib made in preparation for the NRDL negotiation, along with related one-off channel compensation. Upon pralsetinib’s inclusion in NRDL, the anticipated revenue ramp-up in 2026 and beyond is expected to outweigh the short-term negative impact on revenue in 2025. License fee income also decreased substantially, primarily due to the recognition of significant one-time upfront fees and milestone payments received in 2024.
  • Cash and cash equivalents and time deposits were RMB918.7 million as of December 31, 2025.

SUZHOU, China, March 26, 2026 /PRNewswire/ — CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced its 2025 annual results and recent business highlights.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “2025 represents a pivotal strategic inflection point for CStone as we advance our Pipeline 2.0 and accelerate our commercial transformation. Over the past year, we have made highly efficient progress across our innovative pipeline, with our core asset, CS2009, demonstrating compelling efficacy in the latest clinical data. We are on track to initiate multiple global multi-regional Phase III trials by the end of 2026, reinforcing its potential as a next-generation immuno-oncology backbone.

On the commercial front, we continued to expand the global footprint of sugemalimab, while achieving important milestones in China for pralsetinib and avapritinib, including localization and reimbursement access. These efforts have reignited growth momentum in the China market and strengthened the foundation of our commercial platform.

Importantly, while driving business growth, we have maintained a solid financial position, with a cash balance of RMB 918.7 million as of the end of 2025. This financial strength enables us to continue investing in innovation while ensuring disciplined and sustainable operations.

Looking ahead, we remain committed to maximizing the commercial value of our established products while advancing our Pipeline 2.0 with focus and discipline. Through continued innovation and execution, we aim to drive long-term value creation and deliver sustainable returns for our shareholders.”

Business Highlights

For the year ended December 31, 2025, and up to the date of this results announcement, we advanced our innovative pipeline and maximized the commercial value of our in-market assets. Our Pipeline 2.0 achieved significant progress, highlighted by the clinical program CS2009 advancing to Phase II and delivering the first global clinical data for a PD-1/VEGF/CTLA-4 trispecific antibody. We also expanded our therapeutic focus into autoimmune and inflammatory diseases. Commercially, we secured two international agreements for the global commercialization of sugemalimab and obtained regulatory approvals in the European Union (EU) and United Kingdom (U.K.) for Stage III NSCLC. In China, AYVAKIT® (avapritinib) was successfully renewed on the NDRL, while GAVRETO® (pralsetinib) achieved its first-time inclusion. These accomplishments underscore our sustained commitment to developing innovative therapies for patients worldwide.

Clinical Stage Core Assets

CS2009, PD-1/VEGF/CTLA-4 trispecific antibody

  • Global Phase II trial Ongoing

Patient enrollment is active in our global, multicenter Phase II trial. The first patient was dosed in Australia in September 2025. The IND application for this trial was approved by the China National Medical Products Administration (NMPA) in November 2025 and by the U.S. Food and Drug Administration (FDA) in February 2026. This multi-cohort, parallel expansion study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK)/Pharmacodynamics (PD) of CS2009 as monotherapy and in combination regimens in 15 cohorts across 9 solid tumor indications, including NSCLC, colorectal cancer (CRC), extensive-stage small cell lung cancer (ES-SCLC), cervical cancer (CC), gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC), platinum-resistant ovarian cancer (PROC), triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC). Active patient enrollment is ongoing in Australia and China.

  • First-in-class (FIC)/best-in-class (BIC) potential as next-generation I/O backbone

More than 100 late-line patients have been enrolled in Phase I trial. CS2009 has demonstrated a favorable safety and tolerability profile, with no dose-limiting toxicity (DLT) reported and maximum tolerated dose (MTD) not reached. As of the data cutoff of March 17, 2026 with a median follow-up of approximately 6 months. The more mature data continue to reinforce its favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities related to CTLA-4 occurred, and the incidence of Grade ≥3 VEGF-related AEs was low.

CS2009 monotherapy demonstrates potent antitumor activity in later-line “cold” tumors that are not sensitive to PD-(L)1 mAb. An overall response rate (ORR) of 40% was observed in patients with nccRCC, and an ORR of 33.3% in STS, showcasing its broad-spectrum therapeutic potential across multiple tumor types.

Safety data from multiple cohorts of CS2009 combined with standard chemotherapy showed that the combinations were well-tolerated across tumor types, with CS2009 not increasing the incidence or severity of chemotherapy-related adverse events.

Compelling Efficacy has been observed in Lung Cancer. CS2009 monotherapy demonstrates encouraging Phase I/II efficacy in NSCLC. In first-line NSCLC (PD-L1 tumor proportion score [TPS]≥50%), the ORR reached 90%, with a DCR of 100%. In IO-pretreated, AGA negative second-/later-line NSCLC, ORR reached 25%.

  • Efficient and Clearly-Defined Global Development Strategy

Additional Phase I and Phase II clinical data for CS2009 are expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.

The company plans to initiate the first wave of Phase III global multi-regional clinical trials (MRCT) for CS2009 by the end of 2026, targeting indications including NSCLC, CRC, and ES-SCLC.

CS5001, ROR1 ADC

  • Global Phase Ib enrollment ongoing

The global, multicenter Phase Ib clinical trial of CS5001 continues to advance patient enrollment across sites in Australia and China. The trial is designed to determine the recommended Phase II dose (RP2D) and further evaluate the safety, tolerability, PK, and efficacy of CS5001 as monotherapy and in combination with systemic therapies in nine cohorts of selected tumor types. Current enrollment is prioritizing combination cohorts with standard-of-care (SOC) regimens, including CS5001 in combination with R-CHOP (Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone) for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and CS5001 in combination with other SOC therapies for front-line DLBCL. Monotherapy cohorts continue to enroll patients with aggressive and indolent advanced lymphomas. In parallel, CS5001 is being evaluated in advanced solid tumors, both as monotherapy and in combination with the anti-PD-L1 antibody sugemalimab.

  • Promising efficacy and safety profile observed in front line DLBCL

When combined with R-CHOP in the first-line DLBCL setting, no DLTs were observed across the 50–90 μg/kg dose range, with an ORR of 100% and a complete response (CR) rate exceeding 90%. In later-line DLBCL, the combination with standard-of care therapies is currently undergoing dose finding, with no DLTs reported to date and a high ORR already observed.

Commercial Products

CEJEMLY® (sugemalimab), anti-PD-L1 antibody

  • Global expansion and regulatory approvals

Following sugemalimab’s initial marketing authorization in the EU and U.K. for Stage IV NSCLC, the product received additional approvals in the EU in November 2025, and subsequently in the U.K. in February 2026, as monotherapy for adults with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemoradiotherapy (CRT). With these approvals, sugemalimab has become one of only two anti-PD-(L)1 antibodies approved in both the EU and U.K. for Stage III NSCLC, positioning it as a comprehensive therapy option spanning locally advanced, unresectable Stage III to metastatic Stage IV disease. Meanwhile, marketing authorization applications for sugemalimab have been either approved or are under active review in more than ten countries worldwide.

  • Global commercialization driven by strategic alliances

In January 2025, we entered into a partnership with Laboratorios Stein S.A. (SteinCares) to commercialize sugemalimab across ten countries in Latin America (LATAM). This was followed by a partnership with Istituto Gentili S.R.L. (Gentili) in July 2025 to commercialize sugemalimab in 23 countries in Western Europe and the U.K. To date, four partnerships have been executed extending sugemalimab’s international footprint to over 60 countries around the world. Additional partnerships in other markets are under discussion.

GAVRETO® (pralsetinib), RET inhibitor

  • Localized production approved

In July 2025, the China NMPA approved the manufacturing localization application for Pralsetinib Capsules (pralsetinib, 100 mg). In 2026, the supply in China will gradually transition from imported products to end-to-end domestic production – from active pharmaceutical ingredient to finished drug product – significantly enhancing cost efficiency and supply chain resilience.

  • NRDL inclusion

In December 2025, GAVRETO® (pralsetinib, 100 mg) was included for the first time in the latest NRDL released by China’s National Healthcare Security Administration, which took effect on January 1, 2026.

AYVAKIT® (avapritinib), KIT/PDGFRA inhibitor

  • Domestic supply launched

Following the 2024 China NMPA approval for localization production, domestic supply of avapritinib tablets (300 mg and 100 mg) commenced in February 2025, driving anticipated gross margin expansion.

  • NRDL renewal

Following its initial inclusion in December 2023, AYVAKIT® was also successfully renewed on the NRDL in December 2025.

Preclinical/IND-enabling Stage Programs and Proprietary ADC platform

CStone’s preclinical Pipeline 2.0 compromises over nine promising candidates across multispecific antibodies, antibody-drug conjugates (ADC) etc in oncology, immunology and inflammation diseases. We are dedicated to delivering clinical value through the development of these Pipeline 2.0 candidates, which will undergo international, multi-center clinical trials to maximize their global potential.

Our proprietary in-house ADC platform features optimized linkers for tumor-selective payload release and supports multiple Pipeline 2.0 ADC assets, including CS5007 (EGFR/HER3 bispecific ADC), CS5008 (DLL3/SSTR2 bispecific ADC), CS5006 (ITGB4 ADC), CS5009 (B7H3/PD-L1 bispecific ADC), etc.

In May 2025, we presented preclinical data for CS2009, CS5007, and CS5006 at the annual meeting of the American Association for Cancer Research (AACR).

Future and Outlook

Our mission is to deliver transformative therapies through scientific excellence and technological innovation, making high-quality treatments accessible worldwide to benefit patients and their families.

We reaffirm our commitment to advancing a robust and differentiated pipeline by prioritizing internal discovery capabilities and sustained R&D investments, while executing strategic partnerships to unlock the global value of our in-market products. Critical catalysts in 2026 include:

Clinical milestones

  • Accelerate the clinical development of CS2009 and CS5001 while pursuing global partnerships to expedite development.
  • Advance CS5007, CS5006, and other early-stage candidates into clinical stages.

Innovation and technology

  • Strengthen proprietary platforms (e.g., ADC technology) to bolster our early preclinical pipeline.
  • Present key clinical data at major conferences (e.g., ASCO and/or ESMO).

Financial Highlights

International Financial Reporting Standards (IFRS) Measures:

  • Revenue was RMB269.6 million for the year ended December 31, 2025. The revenue is composed of RMB78.3 million from sales of pharmaceutical products (avapritinib, pralsetinib and sugemalimab), RMB167.7 million from license fee income and RMB23.6 million from royalty income of sugemalimab. (1) Revenue from sales of pralsetinib decreased substantially, which is primarily due to price adjustments of pralsetinib made in preparation for the NRDL negotiation, along with related one-off channel compensation. With pralsetinib’s inclusion in the NRDL effective January 1, 2026, the anticipated revenue ramp-up in 2026 and beyond is expected to outweigh the short-term negative impact on revenue. (2) License fee income also decreased to some extent, primarily due to the recognition of significant one-time upfront fees and milestone payments received in 2024.
  • Cost of revenue was RMB218.3 million for the year ended December 31, 2025, primarily due to inventory write-downs charged to cost of revenue and cost associated with an early billing of pralsetinib supply under the Patient Assistance Program covering the period through the first half of 2026 to mitigate customs clearance risks amid trade uncertainties.
  • Research and development expenses were RMB311.5 million for the year ended December 31, 2025, primarily due to an increase in third party contracting costs for clinical trials, including the Phase I/II study for CS2009 and for research programs including CS5007’s IND enabling studies.
  • Administrative expenses were RMB89.0 million for the year ended December 31, 2025.
  • Selling and marketing expenses were RMB83.3 million for the year ended December 31, 2025.
  • Loss for the year was RMB437.0 million for the year ended December 31, 2025. Excluding a one-time negative impact of RMB146.9 million in total from channel compensation and inventory write-downs related to preparation for inclusion of pralsetinib in the NRDL, the loss was RMB290.1 million.
  • Cash and cash equivalents and time deposits were RMB918.7 million as of December 31, 2025.

Non-International Financial Reporting Standards (Non-IFRS) Measures:

  • Research and development expenses excluding the share-based payment expenses were RMB299.5 million for the year ended December 31, 2025, primarily due to an increase in third party contracting costs for clinical trials, including the Phase I/II study for CS2009 and for research programs including CS5007’s IND enabling studies.
  • Administrative and selling and marketing expenses excluding the share-based payment expenses were RMB160.4 million for the year ended December 31, 2025.
  • Loss for the year excluding the share-based payment expenses was RMB413.0 million for the year ended December 31, 2025. Excluding both (1)share-based payment expenses of RMB24.0 million and (2) a one-time negative impact of RMB146.9 million in total from channel compensation and inventory write-downs related to preparation for inclusion of pralsetinib in the NRDL, the loss was RMB266.1 million.

2025 Annual Results Conference Call

The Company will host its 2025 annual results earnings call at 10:00 a.m. (Beijing Time) on Friday March 27, 2026. Please register for the conference in advance through the link: https://s.comein.cn/f79etaud.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring ADCs, multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com. 

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

 

NetDragon Announces 2025 Annual Financial Results

By
Advertorial Desk
-

Cost Optimisation Delivered Notable Results with Operating Profit Up 48% YoY in H2 2025

Final Dividend of HKD0.5 Per Share, AnnoNetDuncing New Shareholder Return Program of No Less Than HKD600 Million

HONG KONG, March 26, 2026 /PRNewswire/ — NetDragon Websoft Holdings Limited (“NetDragon” or the “Company”; Hong Kong Stock Code: 0777), a global leader in building internet communities, announced its financial results for fiscal year 2025 today. NetDragon’s management team will be hosting a conference call and webcast on March 27, 2026 at 10:00am Hong Kong time, to discuss the results and recent business developments.

Dr. Dejian Liu, Chairman of NetDragon, commented: “In 2025, following our strategy to ‘Fully Embrace AI’, the Company further introduced the ‘AI Now’ strategy to fully implement our transformation. We have made encouraging progress across our core verticals of education, gaming and AI+ strategic investments across various sectors. The Company has taken initial steps of transforming into an AI organisation, advancing toward our long-term vision of becoming a global leader in AIGC. Meanwhile, we continued our operational optimisation initiatives. Our overall operating expenses for the year decreased by 22.2% YoY, while operating profit in the second half of the year increased by 47.7% YoY. We expect the benefits of cost optimisation to be further realised in 2026, laying a solid foundation for the Company’s long-term value creation.”

“In education AIGC, leveraging our AI Content Factory, we achieved multiple breakthroughs in product innovation, content creation, and AI integration, building a digital education ecosystem centered on ‘gamified learning’ and laying a strong foundation for scalable, intelligent and immersive learning experiences. Our US-listed subsidiary, Mynd.ai has reduced the segmental operating expenses by 21.1% YoY in 2025, whilst the adjusted EBITDA loss has been reduced by 61.8% QoQ in 4Q 2025. In gaming AIGC, we are actively incubating AI-native games, expanding into new genres and exploring the next-generation gaming experiences driven by AI as the core operational logic. Our flagship IP maintained solid profitability, with the core segmental profit margin of the gaming and application services reaching 27.4%, representing an increase of 3.9 percentage points YoY, whilst the profit scale remained solid. In AI+ strategic investments, we are focusing on unlocking the potential of AI computing power and AIGC production capacity. We will continue to invest in various frontier sectors such as AI and AR .”

“We have also established several significant strategic collaborations to support our long-term development. We have entered into a partnership with Volcengine, ByteDance’s cloud and AI service platform. Together, the two parties will build a deep competitive moat integrating technology, resources, and ecosystem in China’s higher education and vocational education sectors. By scaling the production of next-generation AIGC educational resources, we aim to create a globally co-created and shared innovative education ecosystem. We established a long-term cooperation with Thailand’s Ministry of Higher Education, Science, Research and Innovation (MHESI) to systematically advance an AI-driven ‘Learn-to-Career’ ecosystem in Thailand. With the support of the World Bank, we signed a cooperation agreement with Ministry of Secondary Education of Cameroon (MINESEC) to jointly promote the digital transformation of 250 schools across the country. In addition, our Hong Kong subsidiary Cherrypicks successfully secured the strategic investment from Zhongke WengAI, a leading AI enterprise in China and has repositioned as the exclusive overseas expansion platform and commercialisation partner for Zhongke WengAI in overseas markets. Supported by these strategic partners, We are well placed to accelerate our progress toward becoming a global leader in AIGC creation.”

“Our ongoing efforts in key aspects of sustainable development, such as environmental protection, social responsibility, and corporate governance, have continued to receive widespread recognition. Recently, the Company’s MSCI ESG rating was further upgraded from BBB to A, extending the strong momentum of positive achievements in ESG over the past five years. The company will continue to adhere to its long-term commitment to creating lasting and sustainable value for nature, society, and all stakeholders, including shareholders, customers, and employees.”

“Supported by the positive outcomes of our strategic investments and solid cash position, we remained committed to enhancing shareholder returns. The Board has approved a final dividend of HKD0.5 per ordinary share, bringing total dividends for the year to HKD1.0 per ordinary share. Since announcing a shareholder return program of no less than HKD600 million on 29 August 2025, we have fulfilled our commitment through dividends and share repurchases with the inclusion of the proposed final dividend. The core segmental profit from gaming and application services for the year remained solid at RMB897 million. As of December 2025, our net cash and liquid investments position remained robust at RMB2.0 billion. Based on our confidence in the Company’s long-term sustainable development, we commit to distribute a total of no less than HKD600 million to shareholders over the next 12 months through dividends and share repurchases.”

Fiscal Year 2025 Financial Highlights

  • Revenue was RMB4.5 billion, representing a 26.0% decrease YoY.
  • Revenue from gaming and application services was RMB3.3 billion, representing 73.2% of the Group’s total revenue and a 16.8% decrease YoY primarily attributable to the optimisation of flagship IP to support its long-term development and sustainability.
  • Revenue from Mynd.ai business was RMB1.2 billion, representing 26.7% of the Group’s total revenue and a 43.2% decrease YoY primarily due to the impact of disposal of Singapore early education business in the second half of 2024, and a prolonged demand adjustment cycle. Customer demand is expected to recover as market conditions stabilise.
  • Gross profit was RMB3.1 billion, representing a 20.2% decrease YoY, whereas gross profit margin increased by 5.1 percentage points YoY to 70.3% .
  • Operating expenses decreased by 22.2% YoY to RMB2.6 billion, reflecting the impact of our cost reduction and efficiency improvement measures, which are expected to be fully realised in 2026.
  • Core segmental profit[1] from gaming and application services was RMB897 million, representing a 3.0% decrease YoY, as the lower revenue was partially offset by cost savings. Core segmental profit margin increased by 3.9 percentage points YoY to 27.4%.
  • Core segmental loss[1] from Mynd.ai business was RMB358 million, compared to a loss of RMB297 million in 2024. Core segmental loss[1] for the second half of 2025 was RMB163 million, representing a 12.4% decrease YoY.
  • Profit attributable to owners of the Company was RMB151 million, representing a 51.4% decrease YoY, affected by an impairment loss of cryptocurrencies as of 31 December 2025, as well as one-off expenses associated with the staff optimisation plan.
  • The Company declared a final dividend of HKD0.50 per ordinary share (2024: HKD0.50 per ordinary share), subject to approval at the coming annual general meeting.

Segmental Financial Highlights

FY2025

FY2024

Variance

(RMB million)

Gaming and
application
services

Mynd.ai

business

Gaming and
application
services

Mynd.ai

business

Gaming and
application
services

Mynd.ai

business

Revenue

3,276

1,197

3,938

2,106

-16.8 %

-43.2 %

Gross Profit

2,852

299

3,399

547

-16.1 %

-45.3 %

Gross Margin

87.1 %

25.0 %

86.3 %

26.0 %

+0.8 ppts

-1.0 ppts

Core Segmental
Profit (Loss)[1]

897

(358)

925

(297)

-3.0 %

+20.5 %

Segmental Operating
Expenses[2]

 – Research and
   development

(820)

(193)

(1,227)

(202)

-33.2 %

-4.5 %

 – Selling and
   marketing

(406)

(251)

(488)

(266)

-16.8 %

-5.6 %

 – Administrative

(658)

(211)

(705)

(362)

-6.7 %

-41.7 %

Gaming and Application Services Business

In 2025, revenue from our gaming and application services business amounted to RMB3.3 billion, representing a decrease of 16.8% YoY. We further advanced our strategic focus in the application services business by reducing the equity interests in several subsidiaries, which contributed to the decline in segmental revenue. Segmental operating expenses for the year decreased by 22.1% YoY driven by cost savings from the AI+ strategy with the full-year impact to be realised in 2026. Core segment profit was RMB897 million, representing a decrease of 3.0% YoY only, as the lower revenue was partially offset by the benefits from cost savings for the year.

In the gaming sector, our AIGC capabilities are now delivering tangible results, reinforcing our R&D strategy to focus on AI-native games: Across our flagship evergreen IPs, we have fully leveraged our AIGC capabilities to further shift user activities toward content-driven and culture-driven spending while fostering healthier community development. We also continued to explore incremental growth through format innovation and regional expansion, alongside ongoing investments in content innovation and cultural expression.

The average monthly active users (MAU) of the Eudemons IP increased by 11.1% YoY in 2025, with an increase of 7.1% in the second half of 2025 HoH. Eudemons IP has delivered both HoH and YoY MAU growth for four consecutive half-year periods, ensuring the long-term operation of this evergreen IP and significantly narrowing the YoY decline in overall gaming revenue in the second half. Revenues from Conquer IP and Heroes Evolved IP increased by 6.4% and 21.3% YoY, respectively. Among them, Conquer IP focused on the global dissemination of Chinese martial arts culture, with overseas market revenue accounting for nearly 70% of its total revenue. Heroes Evolved IP adhered to the dual engines of content innovation and esports events, with PC revenue achieving YoY growth for three consecutive years and reaching a record high in 2025.

In 2025, under the guidance of the Fujian Provincial Department of Culture and Tourism, we launched the “Digital Mountains & Seas – Game Empowering Fujian Culture & Tourism” project in collaboration with the Xinhua News Agency and other partners. Our core gaming IPs subsequently entered into cross-sector collaborations with cultural and tourism departments in Fuzhou, Quanzhou, Wuyishan, Nanping, and other regions, deeply integrating with various world heritage, intangible cultural heritage and distinctive cultural tourism IPs. By applying a range of cutting-edge AI technologies such as digital capture and game integration, we create a new paradigm for “Gaming + Culture Tourism.”

Our “AI+Gaming” strategy has been fully implemented in our operations. In 2025, segmental R&D expenses for the gaming and application services decreased by 33.2% YoY, while the share of AI-driven workload in overall game development increased to 25%. Our AI anti-cheat features have covered multiple core gameplay scenarios of Eudemons IP, further improving the in-game environment and ecosystem health. AI companion agents have been fully applied across both Conquer IP and Heroes Evolved IP, significantly improving player retention. In addition, more than 1,000 second-generation intelligent NPCs have been deployed in the Zero IP, delivering encouraging results. We have also successfully established an initial development pathway for AI-native games and built a closed-loop system comprising AI Creative Center, AI Production Center and AI Operations Center. This has significantly reduced the production cost and development cycle of new gaming products, giving us greater resources and more time to continue iterating and experimenting with new ideas, genres and gameplay while enhancing both the scale and quality of our R&D pipeline. We plan to deploy more AI agent employees to increase the share of AI-driven workload to 50% by the end of 2026.

Looking ahead, for mature fields with fully validated business models, we will leverage our AIGC capabilities to replicate success quickly and efficiently. Furthermore, we will position AI-native games as a strategic focus, building a diversified product portfolio centered on new forms of content and user experience. In 2026, the Company plans to expand into new genres, including Match-3 and Roguelike, and will develop multiple new titles.

In the application services sector, we are sharpening our strategic focus and accelerating commercial expansion with education AIGC: Our AI Content Factory has achieved significant advances in automation and intelligence, substantially improving the production efficiency of foundational AIGC elements such as AI textbooks, AI courseware, resource granules, and interactive educational games while further reducing production costs. In the integration of “gamified learning” and “AI+Education,” we continue to make learning more emotionally engaging and immersive. We will remain committed to the core vision that “Knowledge is Experience, Learning is Gaming,” and continue to drive the digital transformation of education globally.

We have recently launched the AI Employee Matrix, fully reconstructing the entire content production chain. AI employees can autonomously handle the complete closed-loop workflow—spanning from creative ideation, intelligent image generation, material refinement to video rendering—7×24 hours without interruption. They precisely take on highly repetitive and time-sensitive tasks, enabling the rapid production of massive volumes of high-quality content. Compared with the traditional human-powered model, this approach significantly shortens production cycles, substantially reduces costs, ensures consistent quality, and enables the shift of content production from “human-driven” to “intelligence-driven”, achieving the goals of standardization, scale, and extreme speed. With the AI Employee Matrix, we are deepening human–machine collaboration, liberating productivity, allowing focus on creativity and quality enhancement, and injecting powerful new momentum of large-scale intelligent content supply into fields such as education.

Our country rollout strategy also continued to make progress. In February 2026, our strategic partnership with Thailand’s Ministry of Higher Education, Science, Research and Innovation (MHESI) was further deepened. Together, we will develop an AI-enabled learning platform, competency assessment framework, and career transition mechanism, building an AI-driven “Learn-to-Career” ecosystem that connects education, skills development and productivity enhancement, and supports Thailand in cultivating a future-ready workforce. In March 2026, the AI-enabled smart classroom jointly developed with Cameroon’s Ministry of Secondary Education (MINESEC) was successfully inaugurated in Yaoundé, the capital of Cameroon, with the Prime Minister of Cameroon and several senior government officials attending the ceremony. This project will also serve as a pilot for the scalable development of digital education across Africa.

In addition, the Company’s strategic investments in frontier technologies and AIGC sectors continue to achieve significant progress: The new-generation AI glasses launched by an AI edge device company we invested in recorded rapid sales growth. Our investee in group live-streaming content production also continued to lead the market, received strong support from the short-video platform, and jointly hosted major live performance events. Currently, we are further expanding our strategic investments and business synergies in various frontier sectors by leveraging AI computing power and AIGC creative capabilities. Looking ahead, our strategic investments will continue to focus on frontier technology such as AI and AR, as well as various cultural and creative industries that can be significantly empowered by AIGC, therefore strengthening synergies with our core business and cultivating new growth drivers for the Company’s long-term development.

Mynd.ai

Notwithstanding industry-wide customer budget uncertainties and increasing challenges of global trade, we are focused on positioning Mynd.ai for future success. We have delivered a major refresh of our flagship product with the launch of our next-generation integrated solution, ActivPanel 10® and Promethean ActivSuite® software and expanded into new product categories through the introduction of ActivPanel LE and ActivPanel D-series, as well as new software and hardware partnerships. Various cost optimisation initiatives were carried out this year to improve our competitive positioning in the market and facilitate further investments in our business.

We continue to evolve our AI-enabled solution roadmap and significantly enhance the interaction of the full ecosystem of software and hardware offerings in a classroom by consolidating cutting-edge AI solutions such as Merlyn Mind and Augment Me.

The key financial highlights for Mynd.ai in 2025 are as follows:

  • Revenue of RMB1.2 billion compared to RMB2.1 billion in the prior year, with the decrease primarily driven by elevated uncertainty amongst our customers regarding future budget allocations, which represents an industry-wide phenomenon that affected the entire education technology market. Customer demand is expected to recover as market conditions stabilise and schools look to refresh their existing technology solutions.
  • Segmental operating expenses of RMB655 million with a decrease of 21.1% YoY, as management continues to implement cost-saving measures to mitigate effects of education technology market headwinds
  • Core segmental loss of RMB358 million compared to a loss of RMB297 million in the prior year. Core segmental loss for the second half was RMB163 million, representing a 12.4% decrease YoY.

Management Conference Call and Webcast

NetDragon’s management team will hold a conference call and webcast at 10:00 am Hong Kong time on March 27, 2026 to discuss the results and recent business developments.

Details of the live conference call and webcast are as follows:

Webcast

https://webcast.roadshowchina.cn/Em83RN

International

+852 3008 3269

Mainland China                                       

HK (China)

4008 070 263

+852 3008 3269

US

+1 516 226 8028

UK

+44 20 3761 0113

Passcode

775091476#

The live and archived webcast of the conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.nd.com.cn/en/category/webcast. Participants of the live webcast should visit the aforementioned website 10 minutes prior to the call, then click on the icon for “2025 Annual Results Conference Call and Webcast” and follow the registration instructions.

About NetDragon Websoft Holdings Limited

NetDragon Websoft Holdings Limited (HKSE: 777) is a global leader in building internet communities, with a long track record of developing and scaling multiple internet and mobile platforms that impact hundreds of millions of users. Over the desktop and mobile internet eras, NetDragon previously established China’s first online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless.  

Established in 1999, NetDragon is one of the most reputable and well-known online game developers in China with a history of successful game titles including Eudemons Online, Conquer Online, Heroes Evolved and Under Oath. In the past 10 years, NetDragon has also achieved success with its EdTech business both domestically and globally. Fully embracing the new AI era, NetDragon is driving its vision of “Infinite Growth” through a dual-focus strategy of “AI+Gaming” and “AI+Education”. With its AI Content Factory empowering operations and working with partners to develop a global learning metaverse, NetDragon is committed to once again building a massive user community in the new AI era.

NetDragon’s overseas edtech business entity, currently a U.S.-listed subsidiary named Mynd.ai, is a global leader in interactive technology and its award-winning interactive displays and software can be found in more than 2 million learning and training spaces across 126 countries.  

For investor enquiries, please contact:
NetDragon Websoft Holdings Limited
Email： ir@netdragon.com

[1] Core segmental profit (loss) figures are derived from the Group’s reported segmental profit (loss) figures (presented in accordance with HKFRS 8), but exclude non-core/operating, non-recurring or unallocated items including redundancy payments, interest expense and exchange difference on convertible and exchangeable bonds and convertible note, impairment loss (net of reversal), fair value loss on investment properties, impairment loss and write off of intangible assets, net gain on disposal of subsidiaries, fair value gain and exchange difference on financial assets at fair value through profit or loss, government grants, fair value gain and exchange loss on derivative financial instruments, reversal of impairment loss of inventories and intangible assets, gain on deemed disposal of an associate, intercompany finance costs, underprovision of tariff expenses in prior years, project expenses, write-down of inventories and waiver of other payables.
[2] Segmental operating expenses exclude unallocated expenses/income such as directors’ emoluments and certain selling and marketing and administrative expenses that have been grouped into SG&A categories on the Company’s reported consolidated financial statements, but cannot be allocated to specific business segments for purpose of calculating the segmental profit (loss) figures in accordance with HKFRS 8.

 

1...883884885...6,684Page 884 of 6,684